Literature DB >> 28379448

MEK and RAF inhibitors: time for a paradigm shift in the treatment of pediatric low-grade gliomas?

Maryam Fouladi1, Stefan M Pfister2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28379448      PMCID： PMC5464452          DOI： 10.1093/neuonc/nox039

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  9 in total

1.  A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas.

Authors:  Yu Sun; John A Alberta; Catherine Pilarz; David Calligaris; Emily J Chadwick; Shakti H Ramkissoon; Lori A Ramkissoon; Veronica Matia Garcia; Emanuele Mazzola; Liliana Goumnerova; Michael Kane; Zhan Yao; Mark W Kieran; Keith L Ligon; William C Hahn; Levi A Garraway; Neal Rosen; Nathanael S Gray; Nathalie Y Agar; Sara J Buhrlage; Rosalind A Segal; Charles D Stiles
Journal:  Neuro Oncol       Date:  2017-06-01       Impact factor: 12.300

2.  Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

Authors:  Georgina V Long; Uwe Trefzer; Michael A Davies; Richard F Kefford; Paolo A Ascierto; Paul B Chapman; Igor Puzanov; Axel Hauschild; Caroline Robert; Alain Algazi; Laurent Mortier; Hussein Tawbi; Tabea Wilhelm; Lisa Zimmer; Julie Switzky; Suzanne Swann; Anne-Marie Martin; Mary Guckert; Vicki Goodman; Michael Streit; John M Kirkwood; Dirk Schadendorf
Journal:  Lancet Oncol       Date:  2012-10-08       Impact factor: 41.316

3.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Authors:  Keith T Flaherty; Jeffery R Infante; Adil Daud; Rene Gonzalez; Richard F Kefford; Jeffrey Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Nageatte Ibrahim; Ragini Kudchadkar; Howard A Burris; Gerald Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Igor Puzanov; Peter Lebowitz; Ajay Singh; Shonda Little; Peng Sun; Alicia Allred; Daniele Ouellet; Kevin B Kim; Kiran Patel; Jeffrey Weber
Journal:  N Engl J Med       Date:  2012-09-29       Impact factor: 91.245

4.  Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

Authors:  Eva Dombi; Andrea Baldwin; Leigh J Marcus; Michael J Fisher; Brian Weiss; AeRang Kim; Patricia Whitcomb; Staci Martin; Lindsey E Aschbacher-Smith; Tilat A Rizvi; Jianqiang Wu; Rachel Ershler; Pamela Wolters; Janet Therrien; John Glod; Jean B Belasco; Elizabeth Schorry; Alessandra Brofferio; Amy J Starosta; Andrea Gillespie; Austin L Doyle; Nancy Ratner; Brigitte C Widemann
Journal:  N Engl J Med       Date:  2016-12-29       Impact factor: 91.245

5.  Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.

Authors:  Matthias A Karajannis; Geneviève Legault; Michael J Fisher; Sarah S Milla; Kenneth J Cohen; Jeffrey H Wisoff; David H Harter; Judith D Goldberg; Tsivia Hochman; Amanda Merkelson; Michael C Bloom; Angela J Sievert; Adam C Resnick; Girish Dhall; David T W Jones; Andrey Korshunov; Stefan M Pfister; Charles G Eberhart; David Zagzag; Jeffrey C Allen
Journal:  Neuro Oncol       Date:  2014-05-06       Impact factor: 12.300

Review 6.  Pediatric low-grade gliomas: implications of the biologic era.

Authors:  Roger J Packer; Stephan Pfister; Eric Bouffet; Robert Avery; Pratiti Bandopadhayay; Miriam Bornhorst; Daniel C Bowers; David Ellison; Jason Fangusaro; Nicholas Foreman; Maryam Fouladi; Amar Gajjar; Daphne Haas-Kogan; Cynthia Hawkins; Cheng-Ying Ho; Eugene Hwang; Nada Jabado; Lindsay B Kilburn; Alvaro Lassaletta; Keith L Ligon; Maura Massimino; Schouten-van Meeteren; Sabine Mueller; Theo Nicolaides; Giorgio Perilongo; Uri Tabori; Gilbert Vezina; Katherine Warren; Olaf Witt; Yuan Zhu; David T Jones; Mark Kieran
Journal:  Neuro Oncol       Date:  2017-06-01       Impact factor: 12.300

7.  Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits.

Authors:  Thomas E Merchant; Heather M Conklin; Shengjie Wu; Robert H Lustig; Xiaoping Xiong
Journal:  J Clin Oncol       Date:  2009-07-06       Impact factor: 44.544

8.  RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

Authors:  Poulikos I Poulikakos; Chao Zhang; Gideon Bollag; Kevan M Shokat; Neal Rosen
Journal:  Nature       Date:  2010-03-18       Impact factor: 49.962

9.  Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas.

Authors:  Jinghui Zhang; Gang Wu; Claudia P Miller; Ruth G Tatevossian; James D Dalton; Bo Tang; Wilda Orisme; Chandanamali Punchihewa; Matthew Parker; Ibrahim Qaddoumi; Fredrick A Boop; Charles Lu; Cyriac Kandoth; Li Ding; Ryan Lee; Robert Huether; Xiang Chen; Erin Hedlund; Panduka Nagahawatte; Michael Rusch; Kristy Boggs; Jinjun Cheng; Jared Becksfort; Jing Ma; Guangchun Song; Yongjin Li; Lei Wei; Jianmin Wang; Sheila Shurtleff; John Easton; David Zhao; Robert S Fulton; Lucinda L Fulton; David J Dooling; Bhavin Vadodaria; Heather L Mulder; Chunlao Tang; Kerri Ochoa; Charles G Mullighan; Amar Gajjar; Richard Kriwacki; Denise Sheer; Richard J Gilbertson; Elaine R Mardis; Richard K Wilson; James R Downing; Suzanne J Baker; David W Ellison
Journal:  Nat Genet       Date:  2013-04-14       Impact factor: 38.330
  9 in total
  2 in total

1.  Pediatric posterior fossa incidentalomas.

Authors:  Danil A Kozyrev; Shlomi Constantini; Deki Tsering; Robert Keating; Sharif Basal; Jonathan Roth
Journal:  Childs Nerv Syst       Date:  2019-09-06       Impact factor: 1.475

Review 2.  Long-Term Follow-Up of Pediatric CNS Tumor Survivors-A Selection of Relevant Long-Term Issues.

Authors:  Maria Otth; Johanna Wyss; Katrin Scheinemann
Journal:  Children (Basel)       Date:  2022-03-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.